1d agoGuruFocusBULLISH 64M&A
Archived explainer. For the current picture see today's RYTM page.
Why Is RHYTHM PHARMACEUTICA (RYTM) Stock Up Today?
By the Top Tier Newswire AI Desk · November 5, 2026 at 12:14 AM ET · reviewed against 19 wire stories
RHYTHM PHARMACEUTICA (RYTM) is up +28.04% in the latest session. Our newswire has captured 19 stories on RYTM across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Rhythm Pharmaceuticals (RYTM) shares surged 28.04% to close at $110.68 on Tuesday. The sharp advance followed a report that AstraZeneca proposed a $10 billion acquisition of the company. The bid, reportedly made last month, values the stock at $124 per share.
What Happened
The primary driver for the move was a report that AstraZeneca offered $124 per share for Rhythm Pharmaceuticals, a total enterprise value of approximately $10 billion. The pharmaceutical company specializes in treatments for metabolic conditions and severe obesity. Trading was briefly halted due to a volatility pause before resuming. The stock closed its best day in nearly 16 months.
Citizens maintains a Market Outperform rating on the stock and recently raised its price target to $166. The company recently announced positive Phase 2 results for Bivamelagon and positive guidance for IMCIVREE in adults with Bardet-Biedl Syndrome.
What The Data Shows
Rhythm Pharmaceuticals has a market capitalization of $6.4 billion. The company is currently unprofitable, with a trailing twelve-month EPS of -3.12 and a net margin of -85.6%. Revenue grew 53.5% over the same period. The stock has a beta of 2.14 and a 52-week range of $74.50 to $122.20.
Over the last eight sessions, the stock gained 23.7%, moving from $89.47 to $110.68. The 52-week tape recorded 20 fresh highs and 7 fresh lows on November 4, 2026. Insider activity over the last 90 days included 6 sells totaling $28.8 million and 0 buys. Notable recent sales include shares sold by President and CEO David P. Meeker on September 14, 2026, and CFO Hunter C. Smith on August 31, 2026.
What To Watch
Investors will monitor the progress of the reported acquisition talks between AstraZeneca and Rhythm Pharmaceuticals. The company’s upcoming earnings date will provide further context on its financial trajectory as it navigates the potential deal.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RYTM by the numbers
Last: $110.68Session: +28.04%7 sessions: +13.93%Coverage: 19 stories / 9 sourcesAI sentiment: 62/100 (bullish)Mkt cap: $6.4B52w: $74.50 to $122.20
The headlines behind the move
1d agoStocktwits NewsBULLISH 74M&A
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
According to a report from The Wall Street Journal, citing people familiar with the matter, AstraZeneca offered $124 per share last month for Rhythm.
1d agoInvesting.com MarketsBULLISH 78M&A
Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report
Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report
1d agoSeeking AlphaBULLISH 74M&A
Rhythm Pharmaceuticals jumps on report AstraZeneca made $10B bid
Rhythm Pharmaceuticals stock surged after a reported $10 billion AstraZeneca bid.
1d agoThe FlyBULLISH 64M&A
AstraZeneca recently made $10B offer to buy Rhythm Pharmaceuticals, WSJ says
1d agoThe FlyNEUTRAL 50General
Rhythm Pharmaceuticals Trading Resumes Thefly News 2
1d agoThe FlyBEARISH 42General
Rhythm Pharmaceuticals trading halted, volatility trading pause
1d agoWSJBULLISH 64M&A
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
Rhythm specializes in treatments for metabolic conditions and severe obesity.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RYTM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RYTM move explainers: 2026-11-05